Anti-CD20 CAR / Orna Therap, Eli Lilly - LARVOL DELTA

Orna Therapeutics Presents Data Highlighting Novel panCAR Approach to Unlock LNP-Mediated RNA Delivery for B Cell Mediated Diseases at the 66th ASH Annual Meeting (PRNewswire) - "A single dose of Orna's anti-CD20 panCAR resulted in a significant reduction in non-human primate (NHP) B cells, with sustained depletion observed 7 days after dosing; In cytotoxicity assays, both the anti-CD20 CAR and an anti-CD19 CAR construct killed human B lymphoblast cell lines in vitro; In vivo, both the anti-CD19CAR and anti-CD20 CAR oRNAs showed significant B cell depletion that manifested as a 75-80% reduction in B cells in peripheral blood, spleen, and bone marrow at 24 hours. This effect was sustained for 7 days after dosing in peripheral blood and bone marrow."

Preclinical • Hematological Malignancies • Oncology